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ABSTRACT 
Microspheres as drug delivery systems have been used widely for oral delivery in the pharmaceuticals formulation. 
Alginates have received much attention as biodegradable polymer for controlled protein delivery. Ovalbumin was used as 
model antigen. The aim of the present research was to evaluate physical characteristics of unlyophilized and lyophilized 
ovalbumin-loaded alginate microspheres produced using aerosolisation technique. Crosslinking agent of BaCl2 and CaCl2 
were studied. Physical characteristics of ovalbumin-loaded alginate microspheres were evaluated in terms of 
encapsulation efficiency, yield, particle size, surface morphology and protein integrity. In vivo immune response was 
studied using hemagglutination test by measuring antibody titre. High entrapment efficiency of unlyophilized ovalbumin-
loaded alginate microspheres using crosslinker BaCl2 and CaCl2 of above 80% and loading of above 65% was produced. 
Entrapment efficiency of lyophilized ovalbumin-loaded alginate microspheres using 10% lactose lyoprotectant and 
maltodextrin were 46% and 54% respectively. For protein loading, ovalbumin-loaded alginate microspheres lyophilized 
using lactose was 28% and using maltodextrin was around 35% respectively. The microspheres size of less than 8μm of 
all formulas using BaCl2 and CaCl2 both lyophilized and unlyophilized were spherical in shapes and formed smooth 
surface. Ovalbumin maintained its integrity after release from alginate microspheres showing ovalbumin’s 45 kDa 
molecular weight indicated its stability has been protected by this delivery system after exposure to acid condition. In 
vivo immune response by hemaglutination test of lyophilized ovalbumin-loaded alginate microspheres with CaCl2 
crosslinker consist of 10% lactose or 10% maltodextrin and unlyophilized microspheres using CaCl2 crosslinker showed 
higher antibody titres than ovalbumin control and blank microspheres. Whereas, unlyophilized ovalbumin-alginate 
microspheres using Ba2+ crosslinking agent resulted antibody titre as low as control and blank microspheres. However, 
No significant effect of immune response was found between microspheres lyophilized with lactose and maltodextrin. In 
conclusion, ovalbumin-loaded alginate microspheres crosslinked using CaCl2 are potential as oral delivery systems and 
results indicated that lyoprotectants were involved in protecting ovalbumin entrapped in alginate microspheres therefore 
able to deliver antigen to the target site in order to induce antibody response.  
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INTRODUCTION 
The rapid development of biotechnology, peptide and 
protein drug substance has been increasingly used for 
therapeutic1. Peptide and protein drug substance has 
several drawbacks, such as low stability, easy and fast to 
deactivation, the short half-life, and the difficulty 
absorbed when given orally. Currently, almost all of 
protein drugs administered through the parenteral route. 
This is what causes the patient discomfort and the price is 
expensive. Many studies were conducted to find a way 
out to overcome this problem1. A major obstacle if the 
vaccine is given orally is the instability and degradation 
of the antigen2. This degradation is due to a protein 
antigen that is very easy denatured by stomach acid. The 
target of antigen uptake is in the Peyer's patches in the 
small intestine. Peyer's patches is the only place in the 
gastrointestinal tract which will absorb the antigen or 
pathogen to be brought to the lymphoid tissue (Gut 
Associated Lymphoid Tissue). If the antigen is denatured 
in the stomach, then there will be no antigen to the target 
so that the immunological response does not appear3. One 
way to avoid denaturation of the protein is to use 
microspheres of oral delivery systems. Microspheres 
commonly contain an active ingredient or core material 
surrounded by a protective layer4. Antigen delivery to the 
carrier in the form of microspheres can prevent 
degradation by the stomach and stimulates the M-cell to 
bring vaccine into the core Peyer's patches. M-cell is a 
cell that can detect the presence of stimulation on payer's 
patches and carry substances adsorbed on the surface of 
the core to the payer's patches5. Not all ingredients are 
absorbed on the surface of the payer's patches can be  
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Table 1. Formulas of ovalbumin-loaded alginate 
microspheres 
 
Formula F1 F2 F3 F4 
Ovalbumin 2,5% V V V V 
Alginate 2,5% V V V V 
CaCl2  V V - V 
BaCl2 - - V - 
Lactose - V - - 
Maltodextrin - - - V 
F1: Formula Microsphere Ca-Alginate; F2: Formula 
Microsphere -lyoprotectant lactose 10% 
F3: Formula Microsphere Ba-Alginate; F4: Formula 
Microsphere -lyoprotectant maltodextrin 10% 
 
Table 2. Efficiency encapsulation and protein loading 
of ovalbumin-loaded alginate microspheres 
Formula Encapsulation 
Efficiency (%) 
Protein loading 
(%) 
F 1 82,62 ± 6,81 86,59 ± 6,81 
F2 46,29 ± 6,81 28,07 ± 6,58 
F3 80,47 ± 9,52 66,86 ± 10,36 
F4 54,15 ± 8,82 35,47 ± 1,60 
 
Table 3. Particle size of Ovalbumin-loaded alginate 
microspheres 
Formula Mean size of particle 
(µm) 
Blank Alginate 
Microspheres 
4,69 μm 
F1 7,52 μm 
F2 5,84 μm 
F3 6,82 μm 
F4 4,97 μm 
carried by the M-cells but only materials that can 
penetrate the intestinal lumen as soluble proteins, 
antigens, bacteria, and viruses6. After arriving at the core 
of the Peyer's patches, these microspheres will rupture 
and release the antigen carries5. Ovalbumin is a protein 
consisting of 385 amino acid residues7. Ovalbumin as an 
antigen to stimulate the formation of antibodies, but a 
poor immunogenic therefore ovalbumin is usually used 
with repeated administration8. Repeated administration of 
the patient causing discomfort, then ovalbumin 
formulated in preparation with controlled release or 
delayed9. Microencapsulation materials contain one or 
more drugs covered by the coating. The core may 
comprise a core material inside and covered by a coating 
on the walls. Microencapsulation generally has particle 
size of between 1-2000µm10. Polymers commonly used as 
a coating material in microencapsulated. Biodegradable 
polymers have demonstrated a high potential to deliver 
peptides and proteins via the oral route11. Alginate is a 
biodegradable polymer. Sodium alginate is a natural 
polymer that has good biocompatibility, does not 
accumulate in the organs of the body, non-toxic, 
biocompatible, and relatively inexpensive. Alginate can 
bind selectively with a solution that is generally in the 
form of a cross junction of multivalent cations (eg Ca2+, 
Ba2+) and virtually unaffected by temperature11. In 
general, Ca2+ is most often used to form a gel, because  
Ca2+ has a low toxicity, the concentration of Ca2+ has a 
significant effect on the stability and pore size of the 
gel12. In addition, ovalbumin-alginate microspheres can 
be formed successfully from the crosslink BaCl2 solution  
that produces high encapsulation efficiency and small 
particles13. The number and size of the cation valence 
compounds determine the continued cross-dimensional 
shape of the polymer formed. Moreover, differences in 
the type of cation are also one of the factors determining 
the selectivity to M cells6. 
 
Fig. 1. Photographs of freeze-dried ovalbumin loaded 
alginate microspheres A: maltodextrin as lyoprotectant; 
B: lactose as lyoprotectant 
 
The encapsulation method used in this study, namely 
ionotropic gelation, is able to maintain the integrity of the 
protein. The entire polyelectrolyte used water soluble so 
that the protein is able to be encapsulated without the use 
of organic solvents that can destroy the protein. This 
method is simple, fast, and relatively inexpensive14.  
To further enhance the stability of the protein, ovalbumin 
is formulated in dry form in oral microspheres  
formulations. In this study, freeze drying is used as an 
alternative to drying without heat that can denature 
proteins and can damage its integrity. In the freeze-drying 
method generally under pressure varies during freezing 
and drying processes that require protectant to protect the 
physical integrity of microparticles formed. Sugar is 
known to stabilize proteins during the process of freeze 
drying15. Sugar was able to create a physical barrier 
between the particles and molecules and reduce diffusion 
and molecular mobility and can prevent protein 
aggregation and degradation. During the drying process, 
the sugar water molecules occupy the hydrogen bonding 
interactions with protein molecules and helps protect the 
integrity16. Therefore, when the lyophilized microspheres 
and solid when dry, the microspheres plus lyoprotectant, 
will remain stable because the integrity of the physical 
form remains sphere, so that the components inside 
remain intact15. Maltodextrin is considered as a potential 
lyoprotectant in lyophilized proteins17. Use lyoprotectant 
generally 5% to 10% for lactose18 as well as for 
maltodextrin17. 
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In the in vivo study, hemagglutination test is very 
important to determine the process of formation of 
antibodies after antigen enters the body, to ascertain 
whether the antigen can be delivered well and is able to 
stimulate the proliferation of T-cells and B-cells19. If the 
antigen successfully delivered, it will be detected in 
serum anti-OVA IgG through agglutination test. 
Agglutination test is one technique that is often used to 
determine the bond between the Ag-Ab in the serum20. 
One of the requirements of this technique is to be in the 
form of particles or antigen-soluble substances, so as to 
form a clot when bound to antibody. There are two 
development agglutination test techniques are widely 
used, namely the indirect hemagglutination and 
hemagglutination. In hemagglutination, antigen attached 
to a carrier in the form of erythrocytes. While indirect 
hemagglutination reacting serum with specific antibodies 
and then newly added antigen to be checked21. Therefore, 
hemagglutination test is absolutely necessary to prove 
that the formulation of ovalbumin microspheres prepared 
to respond immune and whether microspheres delivery is 
effectively deliver vaccine orally. 
This study aims to study the effect of different types of 
lyoprotectant (lactose and maltodextrin) to the physical 
characteristics of the microspheres (microspheres size and 
morphology, encapsulation efficiency and protein loading 
and protein integrity) and also to study in vivo immune 
response of ovalbumin-loaded alginate microspheres. 
 
MATERIALS AND METHODS 
Materials 
Ovalbumin and Sodium alginate (Sigma Aldrich), CaCl2, 
Lactose and Sodium citrate (Bratachem Chemicals) BaCl2 
(Merck), protein quantification kit Sigma; maltodextrin 
p.g, phospate buffer saline pH 7.2, Na EDTA, aquadest, 
red gout blood cell, and mus musculus strain Balb C from 
Pusat Veterenaria Farma (PUSVETMA) Surabaya.  
Methods 
Preparation of Ovalbumin-loaded Alginate microspheres 
using aerosolisation technique 
Sodium alginate (2.5%) was dissolved in 100 mL of 
distilled water and ovalbumin (2.5%) was dissolved in it. 
This solution was then sprayed into 200 mL of 1.5 M 
CaCl2 or BaCl2 solution with a constant speed at a 
distance of 8 cm from the surface of the solution, and a 
pressure of 40 psi. The mixture was stirred at 1000 rpm 
for 2 hours to complete the crosslink reaction. 
Microspheres formed were collected and then separated  
   
Fig. 2. Morphology of wet microspheres: F2, F3 and F4 at 400x magnification 
  
Fig. 3. Scanning Electron Microscope (SEM) of freeze-dried microspheres of formula F3 and F4 
 
F2 F3 F4 
F3 F4 
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by centrifugation at 2,500 rpm for 6 min and washed with 
distilled water twice. Microspheres resuspended in 
lyoprotectant solution (1g/10mL) with concentration 
according to the formula. The suspension was dried by 
freeze dryer at -80 °C for 29 hours. Formulas of 
microspheres can be seen in Table 1. 
Encapsulation efficiency and protein loadings 
The ratio of the actual ovalbumin content in the protein-
loaded microspheres to the theoretical ovalbumin content 
was termed encapsulation efficiency. For protein 
loadings, accurately 50 mL of sodium citrate pH 8.5 was 
added in 400 grams of microspheres and was 
continuously stirred at 1000rpm for 12 hours. The 
absorbance of ovalbumin was measured using UV Vis 
Spectrophotometry using protein quantification kit sigma 
at maximum wavelength of ovalbumin. 
Optical Microscope and Scanning Electron Microscope 
(SEM) study 
The morphology of hydrated ovalbumin-loaded alginate 
microspheres were evaluated using optical microscope, 
while freeze-dried microsphere was observed after freeze-
drying by scanning electron microscope. For SEM 
analysis, The working distance was 10 mm, beam energy 
was 20.0 kV, spot size was 5.0, and magnification was 
5000. The microspheres were loaded on a double sided 
carbon tape put on studs before being examined by SEM. 
In vivo study 
Animals in vivo study has been approved by ethics 
committee and met national ethic standard by Faculty of 
Veterinary Airlangga University. Mice were given orally 
ovalbumin-loaded alginate microspheres or control for 5 
days for all groups of mice. At day 7, animals were 
injected intraperitonially using gout red blood cell 
suspension. At day 17, bloods were taken intracardially 
and were analyzed for the serum or supernatan after 
centrifugation. Hemagglutination study was conducted to 
analyze imune response by measuring IgG titres. 
 
RESULTS AND DISCUSSION 
Ovalbumin-loaded alginate microspheres crosslinked 
using BaCl2 and CaCl2 were successfully produced using 
ionotropic gelation aerosolisation technique. The addition 
of lyoprotectants also used in this research in order to 
prevent denaturation and increase stability of 
microspheres. Furthermore, evaluation of different type 
of lyoprotectants was compared.  
The encapsulation efficiency and ovalbumin loading 
results can be seen in Table 2. Formulas with no 
lyoprotectants added (F1 and F3) showed the highest 
encapsulation efficiency and protein loading at above 
80% similar to previous alginate microspheres13. 
However, size and morphology of unlyophilized 
ovalbumin-loaded alginate microspheres was bigger and 
less smoother compared to lyophilized microspheres.  
In terms of formulas using lyoprotectants, F4 produced 
higher protein encapsulation (54%) and protein loading at 
about 36% than formulas using 10% lactose (F2) which 
resulted less encapsulation efficiency and lower loading. 
This indicated that maltodextrin is a potential 
lyoprotectants in agreement with other researcher17. 
The microspheres sizes of all formulas were found less 
than 8 µm (Table 3). The results showed that the 
incorporation of lactose and maltodextrin as lyoprotectants 
improved functional properties, due to the better physical 
characteristics of the ovalbumin-loaded alginate 
microspheres at concentration 10% w/v at −80 °C freeze 
drying condition. This indicated by smaller microspheres 
were formed at F2 and F4. 
The addition of lyoprotectant prior to lyophilisation 
resulted in a homogenous powder in regard to the blank 
 
Fig. 4. Hemaglutination titre showing IgG level 
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(Figure 1). For wet microspheres, nearly smooth particles 
were formed (Figure 2). As expected, hydrogel alginate 
microspheres obtained with maltodextrin and lactose 
yielded homogeneous and spherical microspheres during 
optical microscopy examination (Figure 3).  
The SEM micrographs revealed the formation of smooth, 
small and spherical microspheres with maltodextrin 
incorporation (Figure 3). The incorporation of 
maltodextrin might lead to a product with more uniform, 
smaller and homogeneous pore structures. This fact was 
in agreement with other authors who indicated that 
saccharides lyoprotectant stabilized bovine plasma 
protein. Furthermore, the microspheres size was found to 
be less than 8µm using optical microscopy and SEM 
examination.  
Possible mechanism of maltodextrin in stabilizes 
ovalbumin loaded alginate microspheres maybe hydrogen 
bonding between sugar or alcohol sugar and protein as an 
important factor during freeze drying. Moreover, the 
existence of maltodextrin as stabilizer avoided aggregation 
of particles; therefore smaller microspheres were 
produced22. 
Integrity structure by SDS PAGE analysis 
Ovalbumin was found to be maintained its integrity 
structure by SDS PAGE analysis. The molecular weight 
of 45kDa was confirmed when compared to protein 
standard marker. From literature, molecular weight of 
ovalbumin was also 45 kDa23. The integrity of 
ovalbumin-loaded alginate microspheres were maintained 
after incubation in acid pH followed by in pH 7.4 after 8 
hours. 
In vivo immune response study 
In vivo hemaglutination study showed that unlyophilized 
ovalbumin-alginate microspheres using Ba2+ crosslinking 
agent resulted antibody titre as low as control and blank 
microspheres (Figure 4). Whereas, lyophilized 
ovalbumin-loaded alginate microspheres with CaCl2 
crosslinker consist of 10% lactose or 10% maltodextrin 
and unlyophilized microspheres using CaCl2 crosslinker 
showed higher antibody titres than ovalbumin control and 
blank microspheres. However, No significant effect of 
immune response showing by IgG titre level was found 
between microspheres lyophilized with lactose and 
maltodextrin. 
Ba-alginate microspheres formed two dimensional 
structures with less empty space provided, this due to 
smaller size of Ba2+ of around 1.74A°, bigger than Ca2+ at 
about 1.14A°. Differences of affinity between Ba2+ and 
Ca2+ was also caused the amount of antigen in the M 
cells, therefore agglutination titre of Ba-alginate 
microspheres was lower than Ca-alginate microspheres. 
Lyophilized alginate microspheres showed the highest 
titre, this indicated that ovalbumin antigen has arrived at 
the target site and ovalbumin microspheres was able to 
across the GI tract barrier in peyer patches produced 
immune response.  O’Hagan (2006) found that vaccine 
delivery using microparticles was able to enhance high 
immune response in animal. Results of this research 
demonstrated the potential of the freeze-dried ovalbumin-
alginate microspheres for oral vaccine delivery system. 
 
CONCLUSION 
High encapsulation efficiency and loading were produced 
successfully by aerosolisation technique of alginate 
polymer and CaCl2 crosslinking agent. Small, smooth and 
spherical microspheres were also confirmed on the 
freeze-dried microspheres using 10% maltodextrin. 
Maltodextrin at concentration 10% were found to be 
better lyoprotectant agent on the ovalbumin-loaded 
alginate microspheres than 10% lactose in terms of 
efficiency, protein loading, size and morphology. 
However, no significant effect of in vivo IgG titre of 
ovalbumin-loaded alginate microspheres produced using 
addition of 10% maltodextrin and lactose lyoprotectant. 
This indicated that the freeze-dried ovalbumin-alginate 
microspheres are potential for oral vaccine delivery 
system. 
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